ADARx Pharmaceuticals Raises $446.3 Million in Upsized US IPO

ADARx Pharmaceuticals raises $446 million in upsized IPO

The San Diego RNA drug developer sold 26.3 million shares at $17 apiece, with AbbVie investing up to $100 million in a concurrent private placement

ADARx Pharmaceuticals raises $446.3 million in upsized US IPO - Regional Media News

Sept 25 (Reuters) - ADARx Pharmaceuticals said on Thursday it had raised $446.3 million in an upsized US initial public offering, reflecting growing investor appetite for biotech listings. The San Diego-based drug developer sold 26.3 million shares at $17 apiece, the top end of its [...]

ADARx Pharmaceuticals raises $446.3 million in upsized US IPO

Sept 25 (Reuters) - ADARx Pharmaceuticals said on Thursday it had raised $446.3 million in an upsized US initial public offering, reflecting growing ​investor appetite for biotech listings. The San Diego-based ‌drug developer sold 26.3 million shares a...

ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering

SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics,...

RNAi drug specialist ADARx raises $446M IPO

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.

ADARx prices $446.3M Nasdaq debut, continuing industry's IPO momentum

A buzzy RNAi startup is going public via an upsized $446.3 million Nasdaq listing, adding to the biopharma industry's high IPO velocity. ADARx Pharmaceuticals, the latest entrant onto the public markets,